SYRA VS NVS Stock Comparison

PerformanceVolatilityAnalyst Price TargetsTechnicalsEarningsProfit
PerformanceVolatilityAnalyst Price TargetsTechnicalsEarningsProfit

Performance

SYRA
10/100

SYRA returned -63.43% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

NVS
100/100

NVS returned 11.56% in the last 12 months. Based on SPY's performance of -13.77%, its performance is above average giving it a score of 100 of 100.

Volatility

SYRA
33/100

SYRA has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.

NVS
44/100

NVS has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

Analyst Price Targets

SYRA

"Analyst Price Targets" not found for SYRA

NVS
67/100

3 analysts offer 12-month price targets for NVS. Together, they have an average target of 0, the most optimistic target put NVS at 0 within 12-months and the most pessimistic has NVS at 0.

Technicals

SYRA

"Technicals" not found for SYRA

NVS
10/100

NVS receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.

Earnings

SYRA

"Earnings" not found for SYRA

NVS
39/100

NVS has missed earnings 5 times in the last 20 quarters.

Profit

SYRA

"Profit" not found for SYRA

NVS
73/100

Out of the last 20 quarters, NVS has had 20 profitable quarters and has increased their profits year over year on 8 of them.

All score calculations are broken down here to help you make more informed investing decisions

Syra Health Corp. Class A Common Stock Summary

Nasdaq / SYRA
Healthcare
Medical - Care Facilities
Syra Health Corp., a healthcare services company, provides health education, population health management, behavioral and mental health, healthcare workforce, and digital health services in the United States. It offers health education services, including medical communications, patient education, and healthcare training; and population health management services, such as analytics as a service, epidemiology, and health equity analytics solutions. The company also engages in developing Syrenity, an on-demand telehealth platform for mental health services. In addition, the company provides healthcare staffing solutions; and digital health solutions comprising digital transformation, cloud and security, artificial intelligence, patient engagement, and health apps. It serves mental health hospitals and organizations, including government agencies, integrated health networks, managed care entities, and pharmaceutical manufacturers. Syra Health Corp. was incorporated in 2020 and is headquartered in Carmel, Indiana.

Novartis AG Summary

New York Stock Exchange / NVS
Healthcare
Drug Manufacturers - General
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.